Dublin, May 24, 2022 (GLOBE NEWSWIRE) -- The "Digital Management of Chronic Injectable Drug Patients" report has been added to ResearchAndMarkets.com's offering.
Digital Management of Chronic Injectable Drug Patients: Technology, Markets, Therapeutics, Strategies and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, opportunities for injection devices that provide the patient with enhanced usability and dosage management via wireless enablement. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
The Evolution of Digital Patient Management For self-administration, adherence with drug therapy and disease management protocols has become a primary concern within the healthcare and pharmaceutical industries. For chronic conditions adherence has a direct effect on the patient's quality-of-life.
Drug injection devices that are designed to address the patient adherence issue by reminding and recording data about patient dosing activity and making it available to HCPs - are gaining interest among industry and managed care participants.
Efforts to enhance adherence have a non-negligible effect on drug formulations and delivery decisions and are a significant factor in the prescribing decisions of most physicians. The connected device ecosystem includes OEM device suppliers, drug developers, human factors consultants and aftermarket third-party devices.
Digital Management of Chronic Injectable Drug Patients - What You Will Learn
- What drug injection devices incorporate digital connectivity technology, how do they work and what new capabilities do they offer to patients and their HCPs?
- What benefits do connected drug injectors provide to patients in the area of improving the patient experience? Patient reported outcomes? HCP/patient communication?
- What therapeutic areas are the current focus of digital enabled devices?
- Who are the companies behind the rise of digital patient management? What are their development activities and corporate alliances and affiliations?
- What is the importance of pharma-device alliances and design partnerships on digital patient management commercialization and market access?
- What does the current market for connected drug injection devices look like? What will it look like in 2028?
- What are the key market drivers for the growth of digital patient management?
Key Topics Covered:
Executive Summary
- Injectable Drug Development Trends
- The Rapid Rise of Prefilled Injection Devices
- Factors Driving Drug Self-Administration
- Design Ergonomics
- Competitive Landscape
- Connectivity Technologies
Wireless Technologies
- Bluetooth
- Cellular
- Near Field Communication
Digitally Enabled Devices
- Recipharm
- Enable Injections
- Insulet
- Merck Serono
- Bayer HealthCare
- SHL Medical
- EMD Serono
- Haselmeier
- Elcam Medical
- Ypsomed AG
- Biocorp
- Biocorp (2)
- Nemera
- Companion Medical
- Sourceboz
- Emperra
- UniSafe
Third Party Devices
- Gocap (Common Sensing)
- EASYLOG (Biocorp)
- Bee (Vigilant)
- Veta EpiPen Smart Case (Aterica)
Digital Management Tools and Services
- Challenges Surrounding Chronic Drug Injection
- Patient Management Software
- Digital Management Initiatives & Services
- Federal Initiatives
- The Role of Telemedicine
Digital Management Tools and Solutions
- Klarus System
Company Profiles
- Bayer HealthCare
- Bee (Vigilant)
- Biocorp
- Companion Medical
- EASYLOG (Biocorp)
- Elcam Medical
- EMD Serono
- Emperra
- Enable Injections
- Gocap (Common Sensing)
- Haselmeier
- Insulet
- Merck Serono
- Nemera
- Recipharm
- SHL Medical
- Sourceboz
- Third Party Devices
- UniSafe
- Veta EpiPen Smart Case (Aterica)
- Ypsomed AG
For more information about this report visit https://www.researchandmarkets.com/r/33jg5p
